In the in vitro study with the use of porcine thyroid tissue, we have shown that under basal conditions (without additional pro-oxidative abuse), both iodine compounds, i.e., KI and KIO 3 (2.550 mM) do not affect oxidative damage to DNA (both nDNA and mtDNA)
Suitable for: Those seeking weight management solutions, especially abdominal fat reduction, as a supplement to diet and exercise
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities
Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue.[2][3] It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.[4] Ipamorelin significantly increases plasma growth hormone (GH).[1][3][5] In addition, ipamorelin stimulates body weight gain in animals.[5] Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.[3] However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH) or cortisol, and is highly selective for inducing the secretion only of GH.[3] Ipamorelin Peptide is under active investigation in a number of cell culture and animal models
This is why oral administration is most defensible for GI-specific indications
doi:10.1073/pnas.84.8.2377
